These include activating mutations in the BCR-associated CD79A/B chains, (present in roughly 23 % of ABC DLBCL cases [77, 78]) the MALT1 activator CARMA1 (roughly 8 % of cases [77, 79]) or the TLR adaptor protein MyD88 (37 % of cases) [80], together with inactivating mutations in A20, a negative regulator of the NF-κB pathway (23 % of cases) [81]. This evidence concerns the gene CARD11 and diffuse large B-cell lymphoma.